{"title":"Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects.","authors":"Tatsuya Hirose, Yasutaka Shinoda, Ayaka Kuroda, Aya Yoshida, Machiko Mitsuoka, Kouki Mori, Yuki Kawachi, Akihiro Moriya, Kouji Tanaka, Atsuko Takeda, Tomoaki Yoshimura, Tadashi Sugiyama","doi":"10.1155/2018/1296717","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Daikenchuto (DKT) is a Kampo medicine used for the treatment of constipation. In this study, we evaluated the effectiveness of DKT against constipation.</p><p><strong>Patients and methods: </strong>Thirty-three patients administered DKT for constipation were selected and divided into low-dose (7.5 g DKT; <i>n</i> = 22) and high-dose (15 g DKT; <i>n</i> = 11) groups. We retrospectively evaluated weekly defaecation frequency, side effects, and clinical laboratory data.</p><p><strong>Results: </strong>Median defaecation frequencies after DKT administration (5, 5.5, 5, and 8 for the first, second, third, and fourth weeks, resp.) were significantly higher than that before DKT administration (2) in all 33 cases (<i>P</i> < 0.01). One case (3%) of watery stool, one case of loose stools (3%), and no cases of abdominal pain (0%) were observed. Median defaecation frequencies in the high-dose group (7 and 9) were significantly higher than those in the low-dose group (4 and 3) in the first (<i>P</i> = 0.0133) and second (<i>P</i> = 0.0101) weeks, respectively. There was no significant change in clinical laboratory values.</p><p><strong>Conclusion: </strong>We suggest that DKT increases defaecation frequency and is safe for treating constipation.</p>","PeriodicalId":13831,"journal":{"name":"International Journal of Chronic Diseases","volume":"2018 ","pages":"1296717"},"PeriodicalIF":0.0000,"publicationDate":"2018-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/1296717","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2018/1296717","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Background: Daikenchuto (DKT) is a Kampo medicine used for the treatment of constipation. In this study, we evaluated the effectiveness of DKT against constipation.
Patients and methods: Thirty-three patients administered DKT for constipation were selected and divided into low-dose (7.5 g DKT; n = 22) and high-dose (15 g DKT; n = 11) groups. We retrospectively evaluated weekly defaecation frequency, side effects, and clinical laboratory data.
Results: Median defaecation frequencies after DKT administration (5, 5.5, 5, and 8 for the first, second, third, and fourth weeks, resp.) were significantly higher than that before DKT administration (2) in all 33 cases (P < 0.01). One case (3%) of watery stool, one case of loose stools (3%), and no cases of abdominal pain (0%) were observed. Median defaecation frequencies in the high-dose group (7 and 9) were significantly higher than those in the low-dose group (4 and 3) in the first (P = 0.0133) and second (P = 0.0101) weeks, respectively. There was no significant change in clinical laboratory values.
Conclusion: We suggest that DKT increases defaecation frequency and is safe for treating constipation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
